Home › Compare › RICOF vs ABBV
RICOF yields 2.92% · ABBV yields 3.09%● Live data
📍 RICOF pulled ahead of the other in Year 9
Combined, RICOF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of RICOF + ABBV for your $10,000?
Ricoh Company, Ltd. provides various office and commercial printing solutions and related solutions worldwide. It offers multifunctional printers, printers, industrial inkjets, garment and production printers, 3D printers, projectors, video and web conference systems, and interactive whiteboards, as well as inkjet heads and modules. The company also provides digital, spherical, single lens reflex, action, and infrared thermography cameras; and automotive stereo cameras, automotive precision machined parts, and small and low energy mobile ICs. In addition, it produces and markets thermal paper and media for food labels, clothing tags, tickets, and handy terminal papers; manufactures and sells watches; and provides magnetoencephalography systems used in brain activity measurement, indoor location information services, bed sensor systems, automated external defibrillators, integrative medical care cooperation systems, and genetic testing substances. Further, the company provides managed print, application/ business process, communication, intelligent workplace, and information technology services; and solar power facility operations and maintenance services, as well as electricity sales services. Ricoh Company, Ltd. serves manufacturing, retail, healthcare, real estate, travel and tourism, and engineering and construction sectors. The company was formerly known as Riken Optical Co., Ltd. and changed its name to Ricoh Company, Ltd. in 1963. Ricoh Company, Ltd. was founded in 1936 and is headquartered in Tokyo, Japan.
Full RICOF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.